Coherus BioSciences, Inc. (NASDAQ:CHRS) posted its quarterly earnings results on Monday. The biotechnology company reported ($1.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.21, Bloomberg Earnings reports. Coherus BioSciences had a negative net margin of 76.85% and a negative return on equity of 827.65%. The business had revenue of $1.40 million during the quarter.

Shares of Coherus BioSciences (NASDAQ:CHRS) traded up 19.35% during mid-day trading on Tuesday, reaching $14.80. 952,471 shares of the company traded hands. The stock’s market capitalization is $759.06 million. Coherus BioSciences has a 52-week low of $12.65 and a 52-week high of $31.98. The stock’s 50 day moving average is $14.27 and its 200 day moving average is $20.24.

Several large investors have recently bought and sold shares of CHRS. State Board of Administration of Florida Retirement System raised its stake in Coherus BioSciences by 0.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,589 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 130 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in Coherus BioSciences by 2,562.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 501,673 shares of the biotechnology company’s stock valued at $14,121,000 after buying an additional 482,828 shares during the last quarter. Teachers Advisors LLC raised its stake in Coherus BioSciences by 1.6% in the fourth quarter. Teachers Advisors LLC now owns 147,753 shares of the biotechnology company’s stock valued at $4,159,000 after buying an additional 2,374 shares during the last quarter. Columbus Circle Investors raised its stake in Coherus BioSciences by 5.6% in the first quarter. Columbus Circle Investors now owns 222,973 shares of the biotechnology company’s stock valued at $4,716,000 after buying an additional 11,792 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its stake in Coherus BioSciences by 8.3% in the first quarter. Candriam Luxembourg S.C.A. now owns 288,000 shares of the biotechnology company’s stock valued at $6,091,000 after buying an additional 22,000 shares during the last quarter. 72.07% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently weighed in on CHRS shares. Maxim Group cut their price objective on shares of Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 12th. Credit Suisse Group reiterated a “buy” rating and issued a $38.00 price objective on shares of Coherus BioSciences in a research report on Friday, April 21st. Citigroup Inc. set a $38.00 price objective on shares of Coherus BioSciences and gave the company a “buy” rating in a research report on Wednesday, May 17th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Coherus BioSciences in a research report on Monday, June 12th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $45.00 price objective on shares of Coherus BioSciences in a research report on Tuesday, June 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $35.90.

TRADEMARK VIOLATION WARNING: “Coherus BioSciences, Inc. (CHRS) Releases Quarterly Earnings Results, Beats Estimates By $0.21 EPS” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/coherus-biosciences-inc-chrs-releases-quarterly-earnings-results-beats-estimates-by-0-21-eps.html.

About Coherus BioSciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Earnings History for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.